Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Immune Monitoring with ImmuKnow(R) in Islet Transplantation May Prove Useful in Reducing the Potential Risks of Rejection, Infection and Other Complications Following Transplant
June 19th, 2009
In an effort to improve the management of pancreatic islet recipients by managing graft stability and reducing immune system risk, Dr. Davide Mineo and colleagues at the Diabetes Research Institute at the University of Miami retrospectively studied 26 islet recipients to correlate ImmuKnow assay values with clinical outcomes over a 2-year period. Among transplant patients with functioning and stable islet grafts, the mean ImmuKnow ATP level was 216ng/mL. In contrast, the mean ImmuKnow ATP level in patients with graft dysfunction or failure was 370ng/mL and among those with infections or drug toxicity, the mean ImmuKnow value was 91ng/mL. In further support, fasting glucose and HbA1c as...
Source: Health Business Week (2009-06-19)
|
